|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4704692A
(en)
|
1986-09-02 |
1987-11-03 |
Ladner Robert C |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5128257A
(en)
|
1987-08-31 |
1992-07-07 |
Baer Bradford W |
Electroporation apparatus and process
|
|
EP0398960B1
(en)
|
1988-01-21 |
1995-12-06 |
Massachusetts Institute Of Technology |
Transport of molecules across tissue using electroporation
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
EP0401384B1
(en)
|
1988-12-22 |
1996-03-13 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
|
US5089261A
(en)
|
1989-01-23 |
1992-02-18 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
CA2019758C
(en)
|
1990-06-25 |
2001-09-04 |
Kevin L. Firth |
Improved electroporation device and method
|
|
US5137817A
(en)
|
1990-10-05 |
1992-08-11 |
Amoco Corporation |
Apparatus and method for electroporation
|
|
US5173158A
(en)
|
1991-07-22 |
1992-12-22 |
Schmukler Robert E |
Apparatus and methods for electroporation and electrofusion
|
|
DE69232137T2
(de)
|
1991-11-25 |
2002-05-29 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
DK0636028T3
(da)
|
1992-04-03 |
2004-07-12 |
Univ California |
Selvorganiserende polynucleotidleveringssystem omfattende et amfipatisk kationisk peptid
|
|
US5304120A
(en)
|
1992-07-01 |
1994-04-19 |
Btx Inc. |
Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
|
|
US5273525A
(en)
|
1992-08-13 |
1993-12-28 |
Btx Inc. |
Injection and electroporation apparatus for drug and gene delivery
|
|
US5318514A
(en)
|
1992-08-17 |
1994-06-07 |
Btx, Inc. |
Applicator for the electroporation of drugs and genes into surface cells
|
|
ATE240394T1
(de)
|
1992-10-23 |
2003-05-15 |
Immunex Corp |
Methoden zur herstellung löslicher, oligomerer proteine
|
|
US5631237A
(en)
|
1992-12-22 |
1997-05-20 |
Dzau; Victor J. |
Method for producing in vivo delivery of therapeutic agents via liposomes
|
|
GB9317380D0
(en)
|
1993-08-20 |
1993-10-06 |
Therexsys Ltd |
Transfection process
|
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
|
US5691188A
(en)
|
1994-02-14 |
1997-11-25 |
American Cyanamid Company |
Transformed yeast cells expressing heterologous G-protein coupled receptor
|
|
AU2946295A
(en)
|
1994-06-27 |
1996-01-19 |
Johns Hopkins University, The |
Targeted gene delivery system
|
|
US5908635A
(en)
|
1994-08-05 |
1999-06-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for the liposomal delivery of nucleic acids
|
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
ES2185770T3
(es)
|
1995-04-08 |
2003-05-01 |
Lg Chemical Ltd |
Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
ATE285477T1
(de)
|
1995-06-07 |
2005-01-15 |
Inex Pharmaceutical Corp |
Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
|
|
US6010613A
(en)
|
1995-12-08 |
2000-01-04 |
Cyto Pulse Sciences, Inc. |
Method of treating materials with pulsed electrical fields
|
|
ATE386809T1
(de)
|
1996-08-02 |
2008-03-15 |
Bristol Myers Squibb Co |
Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
RU2192281C2
(ru)
|
1996-10-11 |
2002-11-10 |
Бристол-Маерс Сквибб Компани |
Способы и композиции для иммуномодуляции
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
CA2277278A1
(en)
|
1997-01-10 |
1998-07-16 |
Life Technologies, Inc. |
Embryonic stem cell serum replacement
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6489458B2
(en)
|
1997-03-11 |
2002-12-03 |
Regents Of The University Of Minnesota |
DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6475994B2
(en)
|
1998-01-07 |
2002-11-05 |
Donald A. Tomalia |
Method and articles for transfection of genetic material
|
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
DE69942334D1
(de)
|
1998-03-02 |
2010-06-17 |
Massachusetts Inst Technology |
Poly-zinkfinger-proteine mit verbesserten linkern
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
US7030215B2
(en)
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US6794136B1
(en)
|
2000-11-20 |
2004-09-21 |
Sangamo Biosciences, Inc. |
Iterative optimization in the design of binding proteins
|
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
|
US6627442B1
(en)
|
2000-08-31 |
2003-09-30 |
Virxsys Corporation |
Methods for stable transduction of cells with hiv-derived viral vectors
|
|
ES2382636T3
(es)
|
2000-10-31 |
2012-06-12 |
Surmodics Pharmaceuticals, Inc. |
Método para producir composiciones para la administración mejorada de moléculas bioactivas
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
HUP0600342A3
(en)
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
CA2478011C
(en)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
EA200401325A1
(ru)
|
2002-04-09 |
2005-04-28 |
Киова Хакко Когио Ко., Лтд. |
Клетки с модифицированным геномом
|
|
CA2489004C
(en)
|
2002-06-13 |
2013-01-08 |
Crucell Holland B.V. |
Agonistic binding molecules to the human ox40 receptor
|
|
PL375144A1
(en)
|
2002-07-30 |
2005-11-28 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
CN101120083B
(zh)
|
2003-10-08 |
2013-03-27 |
威尔森沃尔夫制造公司 |
利用透气性材料进行细胞培养的方法及装置
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
US20050249723A1
(en)
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
|
CA2552788C
(en)
|
2004-01-12 |
2013-09-24 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
AU2005302459A1
(en)
|
2004-10-29 |
2006-05-11 |
University Of Southern California |
Combination cancer immunotherapy with co-stimulatory molecules
|
|
DK2650020T3
(en)
|
2005-05-06 |
2017-01-16 |
Providence Health & Services - Oregon |
Trimeric OX40 immunoglobulin fusion protein and methods for applications.
|
|
TWI466269B
(zh)
|
2006-07-14 |
2014-12-21 |
Semiconductor Energy Lab |
非揮發性記憶體
|
|
EP1894940A1
(en)
|
2006-08-28 |
2008-03-05 |
Apogenix GmbH |
TNF superfamily fusion proteins
|
|
US20100136030A1
(en)
|
2007-02-27 |
2010-06-03 |
Lamhamedi-Cherradi Salah-Eddine |
Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
|
|
EP2176288B1
(en)
|
2007-07-10 |
2015-11-04 |
Apogenix GmbH |
Tnf superfamily collectin fusion proteins
|
|
WO2009045457A2
(en)
|
2007-10-02 |
2009-04-09 |
Rxi Pharmaceuticals Corp. |
Tripartite rnai constructs
|
|
DK2851374T3
(en)
|
2007-12-14 |
2017-06-19 |
Bristol Myers Squibb Co |
Binding molecules to the human OX40 receptor
|
|
US10131904B2
(en)
|
2008-02-11 |
2018-11-20 |
Rxi Pharmaceuticals Corporation |
Modified RNAi polynucleotides and uses thereof
|
|
EP2540740B1
(en)
|
2008-06-17 |
2014-09-10 |
Apogenix GmbH |
Multimeric TNF receptors
|
|
DK2604693T3
(en)
|
2008-07-21 |
2016-05-30 |
Apogenix Gmbh |
Single-chain TNFSF molecules
|
|
CA2746527A1
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
JP5844158B2
(ja)
|
2009-01-09 |
2016-01-13 |
アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ |
三量体形成融合タンパク質
|
|
US20130115617A1
(en)
|
2009-12-08 |
2013-05-09 |
John R. Wilson |
Methods of cell culture for adoptive cell therapy
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
US8809050B2
(en)
|
2009-12-08 |
2014-08-19 |
Wilson Wolf Manufacturing |
Methods of cell culture for adoptive cell therapy
|
|
CN106074591B
(zh)
|
2010-03-24 |
2020-01-14 |
菲奥医药公司 |
眼部症候中的rna干扰
|
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
|
BR112012024049A2
(pt)
|
2010-03-24 |
2017-03-01 |
Rxi Pharmaceuticals Corp |
interferência de rna em indicações dérmicas e fibróticas
|
|
JP6208580B2
(ja)
|
2010-05-17 |
2017-10-04 |
サンガモ セラピューティクス， インコーポレイテッド |
新規のｄｎａ結合タンパク質及びその使用
|
|
AU2011265733B2
(en)
|
2010-06-14 |
2014-04-17 |
Iowa State University Research Foundation, Inc. |
Nuclease activity of TAL effector and Foki fusion protein
|
|
SMT201700185T1
(it)
|
2010-08-23 |
2017-05-08 |
Univ Texas |
Anticorpi anti-ox40 e metodi di uso degli stessi
|
|
PT2614082T
(pt)
|
2010-09-09 |
2018-12-03 |
Pfizer |
Moléculas de ligação a 4-1bb
|
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
EP2675918B1
(en)
|
2011-02-15 |
2017-11-08 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
WO2012129201A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
EP2694089B1
(en)
|
2011-04-05 |
2024-06-05 |
Cellectis |
New tale-protein scaffolds and uses thereof
|
|
US20140234320A1
(en)
|
2011-06-20 |
2014-08-21 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
|
US20140295426A1
(en)
|
2011-07-28 |
2014-10-02 |
Veridex Llc |
Methods for Diagnosing Cancer by Characterization of Tumor Cells Associated with Pleural or Serous Fluids
|
|
CA2845810C
(en)
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
WO2013040557A2
(en)
|
2011-09-16 |
2013-03-21 |
The Trustees Of The University Of Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
CN107058101B
(zh)
|
2011-10-17 |
2021-06-01 |
麻省理工学院 |
细胞内传递
|
|
US9579338B2
(en)
|
2011-11-04 |
2017-02-28 |
Nitto Denko Corporation |
Method of producing lipid nanoparticles for drug delivery
|
|
SG11201407226WA
(en)
|
2012-05-18 |
2014-12-30 |
Wolf Wilson Mfg Corp |
Improved methods of cell culture for adoptive cell therapy
|
|
KR102437522B1
(ko)
|
2012-05-25 |
2022-08-26 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
WO2013182910A2
(en)
|
2012-06-05 |
2013-12-12 |
Cellectis |
New transcription activator-like effector (tale) fusion protein
|
|
RS61391B1
(sr)
|
2012-06-08 |
2021-02-26 |
Alkermes Pharma Ireland Ltd |
Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
|
|
CN104411819B
(zh)
|
2012-06-11 |
2019-05-10 |
威尔逊沃夫制造公司 |
用于过继细胞疗法的改进的细胞培养方法
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
CN105121648B
(zh)
|
2012-12-12 |
2021-05-07 |
布罗德研究所有限公司 |
用于序列操纵的系统、方法和优化的指导组合物的工程化
|
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
|
AU2013359262C1
(en)
|
2012-12-12 |
2021-05-13 |
Massachusetts Institute Of Technology |
CRISPR-Cas component systems, methods and compositions for sequence manipulation
|
|
CA2894684A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
RU2671897C2
(ru)
|
2013-03-01 |
2018-11-07 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
|
|
SMT201800503T1
(it)
|
2013-03-18 |
2018-11-09 |
Janssen Pharmaceuticals Inc |
Anticorpi anti-cd (ox40) umanizzati e loro usi
|
|
US11311575B2
(en)
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
|
CN118562610A
(zh)
|
2013-06-24 |
2024-08-30 |
威尔逊沃夫制造公司 |
用于透气性细胞培养过程的封闭系统装置和方法
|
|
IL312865B2
(en)
*
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
WO2015084897A2
(en)
|
2013-12-02 |
2015-06-11 |
Mirimmune, Llc |
Immunotherapy of cancer
|
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
|
EP3686219A1
(en)
|
2014-02-04 |
2020-07-29 |
Pfizer Inc |
Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
|
|
AU2015273501B2
(en)
|
2014-06-11 |
2021-01-21 |
Polybiocept Gmbh |
Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
SG10201912910PA
(en)
|
2015-07-09 |
2020-02-27 |
Massachusetts Inst Technology |
Delivery of materials to anucleate cells
|
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
|
CN108779475A
(zh)
|
2016-01-12 |
2018-11-09 |
Sqz生物技术公司 |
复合物的细胞内递送
|
|
US12048717B2
(en)
|
2016-06-03 |
2024-07-30 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) agonists to improve ex vivo expansion of tumor infiltrating lymphocytes (TILS)
|
|
MX2019004707A
(es)
*
|
2016-10-26 |
2019-08-12 |
Iovance Biotherapeutics Inc |
Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
|
|
US20190275133A1
(en)
|
2016-11-10 |
2019-09-12 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
US11401507B2
(en)
*
|
2016-11-17 |
2022-08-02 |
Iovance Biotherapeutics, Inc. |
Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
|
|
BR112019013940A2
(pt)
|
2017-01-06 |
2020-02-11 |
Iovance Biotherapeutics, Inc. |
Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
|
|
CA3049165A1
(en)
*
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
KR102619747B1
(ko)
|
2017-01-10 |
2023-12-29 |
넥타르 테라퓨틱스 |
Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
|
|
JOP20190224A1
(ar)
*
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
US11254913B1
(en)
*
|
2017-03-29 |
2022-02-22 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20200224161A1
(en)
|
2017-05-10 |
2020-07-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
BR112019024556A2
(pt)
|
2017-05-24 |
2020-06-23 |
Novartis Ag |
Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
|
|
EP3635097A1
(en)
*
|
2017-06-05 |
2020-04-15 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
WO2019028419A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
|
|
US11713446B2
(en)
*
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
SG11202006541UA
(en)
*
|
2018-01-08 |
2020-08-28 |
Iovance Biotherapeutics Inc |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US20210130779A1
(en)
*
|
2018-04-27 |
2021-05-06 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019217753A1
(en)
*
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CA3112599A1
(en)
*
|
2018-09-20 |
2020-03-26 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
|
TW202039830A
(zh)
*
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
|
|
CA3118493A1
(en)
*
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
JP7710372B2
(ja)
*
|
2018-12-19 |
2025-07-18 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
|
|
KR20260039812A
(ko)
|
2019-02-06 |
2026-03-20 |
신톡스, 인크. |
Il-2 콘쥬게이트 및 이의 사용 방법
|
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
|
WO2021123832A1
(en)
*
|
2019-12-20 |
2021-06-24 |
Instil Bio (Uk) Limited |
Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
|
|
EP4146794A1
(en)
*
|
2020-05-04 |
2023-03-15 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
CA3248034A1
(en)
*
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
|